ESMO 2022 | Will ctDNA replace traditional pathological markers?

Stacey Cohen, MD, University of Washington, Seatlle, WA, discusses whether molecular profiling, such as with circulating tumor DNA (ctDNA) will replace traditional pathological markers, emphasizing ctDNA will be most likely be additive to standard of care. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.